Literature DB >> 5450691

Another genetic variant of haemophilia B: haemophilia B Leyden.

J J Veltkamp, J Meilof, H G Remmelts, D van der Vlerk, E A Loeliger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5450691     DOI： 10.1111/j.1600-0609.1970.tb01873.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN： 0036-553X


× No keyword cloud information.
  13 in total

1.  A less severe form of Haemophilia B Leyden.

Authors:  M Crossley; P R Winship; D E Austen; C R Rizza; G G Brownlee
Journal:  Nucleic Acids Res       Date:  1990-08-11       Impact factor: 16.971

2.  Hemophilia B+ or Bm. First case reported in Italy.

Authors:  A Girolami; G Cella; G Bareggi
Journal:  Blut       Date:  1973-04

3.  Inherited coagulation disorders in India.

Authors:  B C Mehta; M B Agarwal
Journal:  Indian J Pediatr       Date:  1981 Jul-Aug       Impact factor: 1.967

4.  First case report of hemophilia B Leyden in Japan.

Authors:  Atsuki Yamashita; Chiai Nagae; Mika Mori; Tomoko Ashikaga; Tetsuhito Kojima; Masashi Taki
Journal:  Int J Hematol       Date:  2017-02-07       Impact factor: 2.490

5.  Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa.

Authors:  K M Braunstein; C M Noyes; M J Griffith; R L Lundblad; H R Roberts
Journal:  J Clin Invest       Date:  1981-12       Impact factor: 14.808

6.  Hemophilia B with associated factor VII deficiency: a distinct variant of hemophilia B with low factor VII activity and normal factor VII antigen.

Authors:  A Girolami; R Dal Bo Zanon; L De Marco; G Cappellato
Journal:  Blut       Date:  1980-04

7.  Nucleotide substitutions at the -6 position in the promoter region of the factor IX gene result in different severity of hemophilia B Leyden: consequences for genetic counseling.

Authors:  D Vidaud; M Tartary; J M Costa; B R Bahnak; S Gispert-Sanchez; E Fressinaud; C Gazengel; D Meyer; M Goossens; J M Lavergne
Journal:  Hum Genet       Date:  1993-04       Impact factor: 4.132

Review 8.  Clinical significance of gene-diagnosis for defects in coagulation factors and inhibitors.

Authors:  Herbert H Watzke
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

9.  Purification and characterization of an abnormal factor IX (Christmas factor) molecule. Factor IX Chapel Hill.

Authors:  K S Chung; D A Madar; J C Goldsmith; H S Kingdon; H R Roberts
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

10.  A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden.

Authors:  Alister P W Funnell; Michael D Wilson; Benoit Ballester; Ka Sin Mak; Jon Burdach; Natisha Magan; Richard C M Pearson; Frederic P Lemaigre; Kathryn M Stowell; Duncan T Odom; Paul Flicek; Merlin Crossley
Journal:  Am J Hum Genet       Date:  2013-03-07       Impact factor: 11.025
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.